AI Consensus Investment Thesis
Vericel (VCEL) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
NEUTRAL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
NEUTRAL$44
+10.6%5-Year
NEUTRAL$68
+70.2%Latest flagship insight
Cellular Therapy Cash Inflection Confronts Restrictive Valuation Compression In Orthopedic Expansion
Reports show high consensus that completed manufacturing expansion and arthroscopic sports medicine adoption accelerate cash flow generation. However, sharp valuation divergence persists regarding whether surging operational earnings can overcome multiple compression driven by elevated interest rates, commercial payer prior authorization friction, and prospective allogeneic technological obsolescence.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Ray Dalio (Strategist), Universal Investor (Polymath), Superintelligence (Anthropologist), Elon Musk (Visionary), Machiavelli (Insider), J.P. Morgan (Titan), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Vericel at the forecast anchor (2026-09-18): $17,021 in five years versus $13,892 for S&P 500 benchmark.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 41.68 | +4.15% | +4.15% | Year-end insurance deductible exhaustion accelerates fourth-quarter surgical implants, while initial share repurchase execution supports prices. However, elevated Treasury yields and macroeconomic discount-rate pressure cap broader multiple expansion, keeping net quarterly appreciation moderate. |
| Q1 2027 | 41.63 | -0.12% | +4.03% | Annual deductible resets and insurance re-authorizations induce seasonal procedure slowdowns. Headline operating margins contract amid dual-facility depreciation, while persistent central bank rate discipline dampens speculative sentiment, prompting routine first-quarter valuation consolidation across medtech equities. |
| Q2 2027 | 42.71 | +2.59% | +6.72% | Second-quarter surgical volumes rebound as newly trained sports medicine surgeons increase arthroscopic case frequency. Commercial manufacturing runs at Burlington demonstrate early batch efficiencies, expanding gross margins and generating positive operating cash flow. |
| Q3 2027 | 44.28 | +3.68% | +10.65% | Summer sports injury volume maintains consistent biopsy velocity, while federal burn procurement shipments under the BARDA contract provide non-cyclical revenue baselines. Moderating capital spending supports trailing cash flow, offsetting broader equity market multiple stagnation. |
| Q4 2027 | 46.86 | +5.83% | +17.10% | A potent fourth-quarter procedural rush drives record cartilage implant revenue. Operating leverage becomes clearly visible as Burlington fixed overhead absorbs, prompting sell-side earnings revisions and strong year-end institutional accumulation despite prevailing interest-rate headwinds. |
| Q1 2028 | 46.44 | -0.90% | +16.04% | Routine first-quarter procedural lulls and healthcare deductible resets temporarily soften reported quarterly net income. Active open-market share repurchases provide downside price support, buffering equity valuation as investors evaluate full-year operational guidance. |
| Q2 2028 | 48.68 | +4.83% | +21.65% | Spring surgical conversions accelerate alongside encouraging clinical enrollment progress in the MASCOT ankle trial. Higher batch throughput at Burlington lowers unit production costs, reinforcing gross margins above 75% and driving positive earnings momentum. |
| Q3 2028 | 49.69 | +2.07% | +24.17% | Seasonal elective surgery moderation intersects with commercial payer prior-authorization scrutiny, slightly extending biopsy conversion cycles. Steady burn care cash flows and disciplined commercial expenditure preserve operating margins, sustaining orderly trading within the multi-year band. |
| Q4 2028 | 51.99 | +4.62% | +29.90% | Year-end surgical concentration pushes full-year revenue past guidance milestones as Burlington cleanrooms achieve higher capacity utilization. Sinking capital intensity lifts free cash flow conversion, enabling accretive share retirements that enhance per-share fundamental valuation. |
| Q1 2029 | 52.26 | +0.53% | +30.59% | Predictable post-holiday procedure deceleration and winter scheduling delays prompt modest seasonal profit taking. Unencumbered balance-sheet liquidity and zero funded debt insulate operations completely from broader macroeconomic credit volatility, maintaining price stability. |
| Q2 2029 | 54.66 | +4.59% | +36.59% | Pivotal clinical readout announcements for the ankle cartilage indication expand long-term total addressable market expectations. Second-quarter sports medicine case volumes rebound strongly, while automated processing efficiencies lift trailing operating income to fresh highs. |
| Q3 2029 | 56.12 | +2.67% | +40.23% | Core knee repair growth normalizes toward steady mid-teens compounding, while emerging clinical presentations of alternative allogeneic scaffolds temper long-term terminal valuation multiples. Continued share repurchases and international regulatory progress support steady price consolidation. |
| Q4 2029 | 58.89 | +4.94% | +47.16% | Another robust fourth-quarter procedural performance generates record annual operating cash flow exceeding eighty million dollars. High-margin autologous cellular demand confirms business model durability, overcoming broader macroeconomic deceleration through biological standard-of-care entrenchment. |
| Q1 2030 | 59.11 | +0.36% | +47.69% | Annual surgical schedule resets and transitional operating expenses ahead of supplemental regulatory filings induce minor quarterly margin compression. Substantial cash reserves and absence of debt maturities reassure institutional holders, preventing protracted valuation drawdowns. |
| Q2 2030 | 61.53 | +4.11% | +53.76% | Regulatory progress and commercial preparations for expanded extremity indications re-energize orthopedic surgeon interest. Burlington operates at mature batch economics, generating robust quarterly free cash flow that funds ongoing capital return programs. |
| Q3 2030 | 62.34 | +1.31% | +55.77% | Procedural demand demonstrates steady high-single-digit expansion across established sports medicine networks. Terminal growth expectations stabilize around mature medtech benchmarks, keeping valuation multiples aligned with expanding GAAP earnings power rather than speculative platform expansion. |
| Q4 2030 | 64.98 | +4.24% | +62.38% | Record fourth-quarter procedure density across knee and burn franchises delivers strong year-end earnings. Operating margins sustainably approach the high teens as fixed infrastructure costs distribute across mature volume, driving solid annual equity compounding. |
| Q1 2031 | 64.68 | -0.47% | +61.62% | Familiar first-quarter procedural resets and routine healthcare policy debates create mild early-year consolidation. The company's unencumbered balance sheet and dependable recurring biopsy orders establish an elevated valuation floor against cyclical market pullbacks. |
| Q2 2031 | 66.52 | +2.84% | +66.21% | Commercial contributions from expanded indication rollouts and international distribution partnerships supplement core domestic knee revenues. Strong return on invested capital and consistent cash conversion attract long-term value capital, supporting consistent quarter-over-quarter share appreciation. |
| Q3 2031 | 68.12 | +2.41% | +70.21% | The five-year forecast culminates with the enterprise operating as a mature, self-funding regenerative medicine platform. Multiple compression toward realistic peer levels completes, leaving total equity returns driven by durable per-share operational earnings compounding. |
Vericel is executing a fundamental operational transition from capital-intensive cleanroom construction to high-margin cash harvesting. The completion and regulatory approval of the Burlington manufacturing facility terminates peak capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry, permitting gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry to structurally hold above 74% as autologous batch throughput accelerates. Minimally invasive arthroscopic delivery expands the addressable orthopedic surgeon base into high-throughput outpatient centers, while federal burn procurement stabilizes non-dilutive baseline revenues. However, trading at an elevated trailing multiple in a restrictive interest-rate regime leaves the equity highly vulnerable to duration discount compression, requiring sustained operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry expansion to offset systemic multiple derating.
Key insights
- Fixed overhead absorption at Burlington converts incremental biological revenue into expanding operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry, but high equity compensation dilutes headline cash conversion.
- Arthroscopic delivery accelerates surgeon conversion velocity, yet stringent commercial payer prior authorizations and mandatory step therapies continually extend biopsy-to-implantation cash cycles.
- A debt-free balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry and authorized share repurchases provide immediate downside support, but long-term terminal valueterminal valueThe present value of all future cash flows beyond the explicit forecast period.View full glossary entry remains exposed to competing allogeneic cartilage platforms.
Vericel is shifting from building expensive production factories to generating steady cash from its knee cartilage and burn treatments. Its newly approved manufacturing facility and simpler surgical tools help doctors treat more patients with less surgical trauma. While high interest rates keep company valuation multiples under pressure, strong cash balances, zero debt, and growing surgical adoption provide a solid operational foundation.
Key insights
- Completing the manufacturing expansion releases significant operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry to fund share buybacks and business growth.
- Less invasive arthroscopic tools attract more orthopedic surgeons, though insurance approval hurdles can delay scheduled operations.
- Having zero debt protects the business from credit stress, though emerging single-stage cartilage therapies remain a future threat.
Deep Dive
Market consensus views the company as an expensive specialty biopharma asset trading near eighty-four times trailing earnings in a restrictive monetary environment. Prevailing commentary anchors on post-expansion facility depreciation, quarterly surgical seasonality, and insurer prior-authorization friction. Investors largely assume that elevated interest rates will mechanically cap valuation multiples, treating autologous cell therapy as an artisanal, niche procedure nearing domestic market saturation.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Market consensus views the company as an expensive specialty biopharma asset trading near eighty-four times trailing earnings in a restrictive monetary environment. Prevailing commentary anchors on post-expansion facility depreciation, quarterly surgical seasonality, and insurer prior-authorization friction. Investors largely assume that elevated interest rates will mechanically cap valuation multiples, treating autologous cell therapy as an artisanal, niche procedure nearing domestic market saturation.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The crowd underestimates underlying cash generation, creating mild underpricing on a cash-flow basis despite optical multiple stretch. The market fixates on trailing GAAP earnings depressed by facility buildout costs, missing that capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry collapsed from 27% of revenue to single digits. This cliff unleashed forty-nine million dollars in trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. While arthroscopic delivery and fixed-cost absorption expand normalized owner earningsowner earningsAn estimate of cash available to owners after operating costs, taxes, and the capital spending needed to maintain competitive capacity.View full glossary entry, the analytical challenge remains that elevated risk-free yieldsrisk free yieldsYields on instruments treated as having negligible default risk for a given currency and maturity.View full glossary entry will compress terminal multiplesterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry, dampening equity gains relative to cash flow.
Repricing Catalyst
What could make the market recognize and close that gap? The decisive catalyst cluster centers on consecutive quarterly earnings releases throughout 2027 confirming gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry holding above 75% alongside annual free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry exceeding sixty million dollars. Accelerating biopsy conversion from MACI Arthro adoption and steady federal NexoBrid deliveries will demonstrate unmistakable operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry. This cash inflection will force institutional screening models to look past headline trailing multiples, prompting an upward valuation repricing as share buybacks reduce share floatfloatThe number of shares available for public trading in the market.View full glossary entry.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Balanced
- Volatility
- Moderate
- Cycle position
- Growing Awareness
Sentiment converges around growing operational awareness, but opinions sharply diverge between models expecting aggressive valuation reratingvaluation reratingA change in the valuation multiple assigned to a business or asset after expectations about growth, quality, or risk change.View full glossary entry and those anticipating heavy discount-rate multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. This tension dictates whether near-term equity gains mirror operational cash flow acceleration or remain subdued.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop represents a mixed setup. A hawkish monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry and elevated Treasury yields impose direct valuation compression on long-duration equities. However, zero debt, over two hundred million dollars in liquidity, and biologically non-discretionary joint preservation demand completely insulate core operations and cash generation from credit tightening and broader economic volatility.
Advisor Disagreement
What do our AI Advisors disagree about most? The core debate centers on whether surging operational cash flows can overpower macro valuation headwinds. Bullish views argue that the post-Burlington capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry collapse and arthroscopic surgeon expansion will unlock operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry above 20% and fuel substantial buybacks, driving aggressive equity rerating. Conversely, skeptical views contend that paying eighty-four times trailing earnings in a 5% interest rate environment guarantees severe multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry, as bespoke autologous manufacturing faces structural margin ceilings and terminal allogeneic competition. Resolving this tension requires tracking whether quarterly GAAP sustainably exceed 12% through 2027.
Base-Case Forces
Event Risk ScoreModerate59/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Burlington facility manufacturing scale unlock | Operational Efficiency | +32% | +52% | FDA approval and commercial ramp of the Burlington production center eliminate historical cell-culture bottlenecks, tripling batch capacity. Concentrating manufacturing under automated cleanrooms spreads fixed labor and facility overhead across escalating volumes, expanding gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry toward 76%. This structural leverage converts incremental cartilage repair revenue directly into substantial operating profit and unencumbered free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. |
| MACI Arthro arthroscopic surgeon expansion | Innovation And Product | +28% | +45% | Commercial rollout of MACI Arthro instrumentation eliminates invasive open arthrotomy, expanding the addressable sports medicine orthopedic surgeon base from five thousand to over seven thousand clinicians. Arthroscopic delivery lowers patient recovery friction and accelerates biopsy-to-implant conversions, driving durable 20% annual cartilage repair volume growth and compounding high-margin biologic revenue over the five-year forecast horizon. |
| Autologous biologic monopoly and pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry | Competitive Positioning | +22% | +28% | Holding the sole FDA-approved autologous cellularized scaffold for knee cartilage repair creates an impenetrable regulatory and clinical barrier. Replicating proprietary patient-specific culturing protocols requires years of clinical trials and substantial capital investment, completely excluding generic competition. This monopolistic positioning secures premium pricing above $60,000 per implant, insulating gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and cash generation from inflationary shocks. |
| Post-capexcapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry cash allocation and repurchases | Capital Allocation | +18% | +20% | With major Burlington construction concluded, capital expenditurecapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry intensity collapsed from 27% of revenue to maintenance levels below 8%. Generating nearly $50 million in trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry allows management to deploy its $200 million share repurchase program. Funded entirely by operating liquidity with zero debt, systematic share retirements neutralize compensation dilutiondilutionReduction in ownership percentage for existing shareholders caused by the issuance of new equity shares.View full glossary entry and accretively compound earnings per share. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Elevated interest rate valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry compression | Macroeconomic And Macrofinancial | -24% | -4.0% | Trading at an elevated trailing earnings multipleearnings multipleThe ratio of share price to earnings per share used to determine stock valuation.View full glossary entry near 84x and 52x EV/EBITDAearnings before interest taxes depreciation and amortizationEarnings before interest, taxes, depreciation, and amortization (EBITDA) measures operating performance before financing, tax, and certain accounting charges.View full glossary entry leaves the stock acutely vulnerable to higher-for-longer discount rates. Benchmark 10-year Treasury yields hovering near 5% systematically compress long-duration equity multiples. Even robust operational earnings execution will see headline stock price appreciation heavily dampened as institutional valuation models derate specialty biopharma multiples toward historical norms. |
| Commercial insurer prior authorization friction | Regulatory | -14% | -16% | Commercial health insurers and Medicare Advantagemedicare advantageUS private health plans approved by Medicare to provide covered benefits to enrolled members.View full glossary entry plans continue enforcing aggressive utilization management, mandating step therapies and extensive conservative treatment documentation before approving costly cell implants. This administrative gatekeeping elongates the sales cycle from biopsy harvest to surgical implantation, increasing cancellation rates and requiring elevated corporate expenditures on reimbursement support personnel to defend procedural conversions. |
| Autologous cellular logistics margin ceiling | Operational Efficiency | -12% | -15% | Personalized autologous therapy requires harvesting living human tissue, specialized cryogenic transport, individual batch culturing, and re-implantation. These bespoke operational logistics impose an irreducible cost floor that automation cannot fully eliminate. Cleanroom labor wage inflationwage inflationA sustained increase in employee compensation across a workforce, industry, or economy.View full glossary entry and single-facility processing concentration permanently cap operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry around 20%, preventing the company from achieving software-like biopharma profit conversion. |
| Burlington facility depreciation accounting drag | Operational Efficiency | -10% | -14% | Capitalizing the state-of-the-art Burlington manufacturing complex more than doubled annual depreciation and amortization charges above $13 million. Maintaining dual facility operations during ongoing validation while cleanroom throughput scales introduces significant fixed overhead. This ongoing non-cash accounting drag compresses reported GAAP operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry to single digits, discouraging conservative value investors who screen strictly on optical net income. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Disruptive off-the-shelf allogeneic cartilage emergence | 22% | -38% | A competing biotechnology developer could publish breakthrough Phase 3 clinical efficacy for an off-the-shelf allogeneic or synthetic chondral scaffold by 2029. Eliminating the invasive primary biopsy surgery and weeks of individualized cleanroom culturing would induce rapid surgeon substitution toward single-stage repairs. This technological disruption would rapidly dismantle the company's autologous moat, forcing steep price concessions and triggering terminal multipleterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry collapse. |
| Burlington manufacturing cleanroom contamination shutdown | 16% | -40% | A severe microbial contamination event or adverse FDA cGMP inspection at the centralized Burlington cell-processing facility could force an immediate commercial suspension. Because autologous cell therapy involves perishable, patient-specific living tissues that cannot be inventoried or rapidly outsourced, an operational shutdown would instantly vaporize quarterly revenues, incur substantial remediation costs, and inflict lasting reputational damage among prescribing orthopedic surgeons. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| MACI ankle talar indication label clearance | 36% | +32% | Successful pivotal readout from the Phase 3 MASCOT clinical study could trigger supplemental FDA approval for talar cartilage defects of the ankle by 2028. Ankle cartilage repair represents an underserved domestic market of over twenty thousand annual procedures with zero approved cellular competitors. Leveraging established sports medicine sales rails would unlock over $1 billion in incremental market opportunity, expanding earnings power by 30%. |
| International regulatory authorization and European commercialization | 30% | +28% | Securing marketing authorization from the UK MHRA followed by European distribution partnerships would establish the company's first commercial presence outside the United States. Utilizing Burlington's export-qualified capacity to serve European sports medicine demand would generate high-margin royalty and transfer revenues without heavy overseas commercial infrastructure outlays. This catalyst remains under 50% probability due to rigorous single-payer cost-effectiveness assessments across European health systems. |
Company Financial Analysis
Vericel Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Vericel has successfully transitioned from an unprofitable clinical-stage development firm into a commercial business generating positive operating income. For the trailing twelve months ended June 2026, revenue expanded to $306 million while net income reached $24.2 million, driven by strong 23% growth in MACI knee implants and growing burn treatment sales. This performance confirms that customer demand is expanding steadily. However, reported accounting profits experience sharp seasonal fluctuations. First quarters frequently show net losses due to annual insurance deductible resets, while fourth quarters deliver outsized profits as patients complete year-end procedures. The fundamental financial trajectory remains positive as rising case volumes absorb fixed corporate overhead.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 276.3M | USD 16.5M | USD 24.7M |
| 2024 | USD 237.2M | USD 10.4M | USD -5.8M |
| 2023 | USD 197.5M | USD -3.2M | USD 7.8M |
| 2022 | USD 164.4M | USD -16.7M | USD 10.1M |
| 2021 | USD 156.2M | USD -7.5M | USD 21.1M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | >100x | TTM | Native | USD / USD |
| 2024 | >100x | TTM | Native | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Gross profit margins have expanded structurally from under 69% in 2023 to over 74% in 2025, driven by premium product pricing and improved cell-culturing efficiency. Because autologous cell therapy manufacturing costs are largely fixed, processing higher patient volumes through automated Burlington bioreactors allows gross margins to hold near 75%. Below gross profit, GAAP operating margins sit near 6% due to high facility depreciation, commercial sales force investments, and stock-based employee compensation. As specialized sales territories mature and batch throughput expands across the forecast horizon, operating leverage should gradually expand operating profitability toward mid-teens.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 11M | 4.0% | 6.0% |
| 2024 | USD 4.5M | 1.9% | 4.4% |
| 2023 | USD -6.5M | -3.3% | -1.6% |
| 2022 | USD -17.1M | -10.4% | -10.2% |
| 2021 | USD -7.9M | -5.0% | -4.8% |
Balance sheet and leverage
AI Review
Vericel commands a fortress balance sheet characterized by zero funded bank debt and approximately $227 million in cash and short-term investments as of mid-2026. A current ratio above 5.0 and an undrawn $150 million credit line demonstrate excellent liquidity, completely protecting business operations from high interest rates and credit market volatility. While reported financial liabilities include roughly $93 million in long-term building lease obligations for manufacturing cleanrooms, these represent ongoing operational facilities rather than refinancing debt. Management possesses total balance-sheet freedom to self-fund clinical trials and repurchase shares without depending on external capital.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 98.3M | USD 137.5M | USD 1.8M net cash | 5.03x |
| 2024 | USD 98.9M | USD 116.2M | USD 24.3M net debt | 4.23x |
| 2023 | USD 88M | USD 109.6M | USD 19M net debt | 4.49x |
| 2022 | USD 47.6M | USD 119.5M | USD 3.5M net cash | 4.99x |
| 2021 | USD 50.2M | USD 103.4M | USD 18.1M net cash | 6.08x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management has completed a major multi-year spending cycle after constructing and commissioning its advanced manufacturing plant in Burlington, Massachusetts. Capital spending peaked in 2024 at 27% of revenue during cleanroom construction before falling sharply to under 10% in 2025 and lower in 2026. This deliberate reduction in construction spending has liberated substantial operational liquidity. Because foundational manufacturing capacity is now installed for the next decade, ongoing maintenance investment requires less than 5% of revenue. This shift allowed trailing free cash flow to surge to nearly $50 million, enabling management to direct surplus capital toward an authorized $200 million share repurchase program.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 27.2M | USD 27.6M |
| 2024 | USD 64M | USD 24.8M |
| 2023 | USD 27.5M | USD 21M |
| 2022 | USD 7.6M | USD 19.9M |
| 2021 | USD 7.9M | USD 16.3M |
Quarterly Forecast Scenarios
Vericel Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $38.02 | $42.05 | $44.02 | $750.26 | |
| $38.75 | $41.76 | $44.52 | $736.44 | |
| $37.97 | $43.24 | $47.63 | $743.40 | |
| $39.49 | $44.90 | $50.49 | $755.15 | |
| $41.47 | $47.72 | $54.53 | $776.22 | |
| $39.81 | $47.45 | $56.71 | $787.13 | |
| $41.00 | $49.87 | $60.68 | $802.83 | |
| $40.18 | $51.17 | $63.72 | $812.05 | |
| $42.59 | $53.96 | $68.18 | $839.18 | |
| $40.46 | $54.16 | $70.22 | $850.50 | |
| $42.08 | $56.74 | $74.44 | $872.39 | |
| $40.82 | $58.59 | $78.16 | $885.51 | |
| $42.86 | $61.73 | $82.85 | $909.56 | |
| $41.57 | $62.15 | $85.33 | $916.13 | |
| $43.24 | $64.97 | $90.31 | $936.51 | |
| $42.37 | $66.42 | $94.82 | $947.34 | |
| $44.49 | $69.51 | $101.46 | $969.59 | |
| $42.71 | $69.46 | $103.49 | $979.99 | |
| $43.99 | $71.71 | $108.66 | $999.60 | |
| $44.07 | $73.64 | $113.01 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The reports exhibit strong independent consensus regarding operational fundamentals: the Burlington facility completion eliminates capital expenditure drag, releasing approximately $50 million in trailing free cash flow, while MACI Arthro expands surgeon adoption. However, reports sharing optimistic assumptions often extrapolate unadjusted EBITDA without adequately deducting stock compensation, facility depreciation, and payer friction. Conversely, the strongest credible contrarian perspective rightly emphasizes that paying 84x trailing earnings in a 5% interest-rate regime creates severe multiple compression risk, even if revenue compounds above 15%. Extreme outlier projections—such as frictionless multiple expansion to $140 or rapid catastrophic obsolescence below $22—lack near-term empirical backing. Weighting therefore favors reports that balance proven cash-flow inflection against rigorous discount-rate discipline, rewarding frameworks that reconcile operating leverage with structural multiple contraction while downweighting unhedged momentum narratives.
Universal Investor AI
The Polymath
GPT-6 AstraDemonstrating superior analytical rigor, this report reconciles primary SEC filings, verifies lease liabilities versus funded debt, and accounts for equity compensation drag. Its sober 9% annual return expectation properly discounts platform hype, warranting the highest weight.
Universal Investor AI
The Polymath
Opus 5Backed by primary earnings transcript verification, this analysis sharply identifies the duration tax on high multiples and highlights the stock compensation gap in adjusted EBITDA. Its grounded, cash-focused trajectory provides exceptional decision utility.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashGrounding its thesis in forensic verification of post-capex cash generation, this report presents a balanced view of operating leverage versus terminal multiple contraction. Its reasonable 26x forward multiple and focus on conversion watchpoints justify an above-average weight.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThis analysis excels by focusing on owner earnings, working capital stability, and fortress balance-sheet insulation. Its conservative terminal multiple of 22x and clear-eyed view of sunk Burlington capex provide sound economic reasoning that warrants strong weighting.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThis report correctly identifies that heavy non-cash facility depreciation obscures underlying owner cash flows. Its focus on autologous biologic moats and realistic 25x terminal owner-earnings multiples provides credible long-term perspective, supporting a solid weight.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThis report accurately identifies the thermodynamic bottlenecks of autologous manufacturing and the mathematical inevitability of multiple compression in a high-rate regime. However, it overstates near-term obsolescence from allogeneic competitors, warranting a moderate weight that values its disciplined valuation caution.
Michael Burry AI
The Vulture
Gemini 3.8 FlashOffering essential contrarian rigor, this report highlights the vulnerability of an 84x trailing multiple against 5% sovereign bond yields and notes insider selling. While somewhat overly punitive regarding top-line durability, its valuation discipline survives scrutiny.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThis report thoroughly examines post-Burlington free cash flow mechanics and institutional NexoBrid integration. However, its baseline assumption of 23% operating margins somewhat downplays specialized biologic selling expenses, warranting a balanced intermediate weight.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashProviding excellent analysis of deductible-driven seasonality and cleanroom thermodynamic constraints, this report realistically models earnings growth being partially consumed by multiple compression toward 28x. Its balanced causal framework justifies an above-average weight.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashThe analysis effectively captures regulatory moats under FDA biologics oversight and sovereign backing via BARDA. However, it underestimates rate-driven multiple compression and models aggressive long-term price targets that rely on flawless execution across international markets.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashThis perspective provides valuable insight into arthroscopic adoption mechanics and fixed-cost absorption. Nevertheless, its projection of Adjusted EBITDA margins reaching 37% minimizes ongoing cleanroom labor inflation and commercial salesforce overhead, requiring a measured weighting.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashThe framework effectively links economic machine cycle transitions to cash flow liberation and zero-debt balance sheet resilience. However, its compounded trajectory assumes sustained multiple expansion that conflicts with higher-for-longer cost-of-capital realities.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashWhile thoroughly evaluating the Burlington manufacturing scale and commercial monopoly dynamics, this assessment models extreme multiple resilience and aggressive earnings targets. It severely downweights monetary tightening drag and payer step-therapy frictions, justifying a reduced relative allocation.
Universal Investor AI
The Polymath
Gemini 3.8 FlashWhile identifying commercial inflection drivers and buyback dynamics, this report relies on overly aggressive price trajectory checkpoints that outpace plausible multiple compression constraints. Its optimistic compounding path requires a discounted weighting.
Research Provenance
References & Context
This Vericel consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 61 deduplicated sources retained for this batch.
- 01Package Insert - MACIfda.gov
- 02Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
- 03https://www.sec.gov/Archives/edgar/data/887359/000162828026050815/ex991earningsreleaseq22026.htm?utm_source=openaisec.gov
- 04Press Release of Vericel Corporation ...sec.gov
- 05vcel-20251231sec.gov
- 06vcel-20260630sec.gov
- 07VERICEL CORPORATION - DEF 14Asec.gov
- 08Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program - BioSpacebiospace.com
- 09VCEL Stock Quote Price and Forecast | CNNcnn.com
- 10Vericel Corp (VCEL) Q2 2026 Earnings Call Transcript - Equiblesequibles.com
- 11Vericel Q2 Earnings Call Highlightsfinance.yahoo.com
- 12Vericel Q2 2026 slides: 22% revenue growth, first buyback By Investing.cominvesting.com
- 13Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility | Vericel Corporationinvestors.vcel.com
- 14Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance | Vericel Corporationinvestors.vcel.com
- 15Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results | Vericel Corporationinvestors.vcel.com
And 46 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.